ClinicalTrials.gg
TerminatedNCT00637780Updated Feb 23, 2017Results posted

Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis

A Phase 4 interventional study of Sulfasalazine in Arthritis, Juvenile Rheumatoid, sponsored by Pfizer. Terminated at 2 sites in 2 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-02-23.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Why this study was terminated
Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Arthritis, Juvenile by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Juvenile · Pfizer.

Started
2010
the only one that year
Phase 4
Only one
of the 10
Registered
2nd of 10
by date

Among the 10 studies in Arthritis, Juvenile by Pfizer, this one is the only one that started in 2010, is the only one in phase 4, and was the 2nd registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

1 of the 10 studies in Arthritis, Juvenile by Pfizer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Arthritis, Juvenile by Pfizer, or all of them as a file.
02

Study summary

This study will characterize the steady state pharmacokinetics of sulfasalazine delayed release tablets in pediatric Juvenile Idiopathic Arthritis patients. Data from this study will fulfill the post approval commitment to the FDA.

03

Conditions studied

  • Arthritis, Juvenile Rheumatoid

Browse trials for

Keywords

  • Sulfasalazine delayed release tablets
  • azulfidine entabs
  • Pharmacokinetics
  • Juvenile Idiopathic Arthritis (JIA)
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a diagnosis of oligoarticular, polyarticular, psoriatic or enthesitis-related JIA as determined by ILAR criteria. Patients who have been continuously treated with generic sulfasalazine delayed release formulation and have tolerated the product for at least 3 months prior to study enrolment and who are switched to Azulfidine-EN at least 8 days prior to Day 0 are eligible.
  • Patients must be at least 6 years of age and has not reached his/her 18th birthday prior to the Baseline Visit (Day 0).
  • Onset of JIA must have occurred prior to the patient's 16th birthday.
  • Patients must weigh at least 20 kg.
  • Patients must be on sulfasalazine 500 mg delayed release tablets and the total daily dose must be within the specified range of 30-60 mg/kg/day with a maximum daily dose of 3 g/day

Exclusion criteria

Exclusion Criteria:

  • Patient currently with systemic features of systemic JIA.
  • to sulfasalazine , its metabolites, sulfonamides or salicylates.
  • History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • Inability to swallow whole (uncrushed) sulfasalazine 500 mg delayed release tablets as required by protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    1

    Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 6 days

    Drug: Sulfasalazine

Interventions

  • Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 7 days. Blood sampling for Pharmacokinetic assessment to be performed on Day 7

    Also known as: AZULFIDINE EN-tabs Tablets

06

What researchers measure

Primary outcomes

  1. Sulfasalazine Steady State Maximum Plasma Concentration (Cmax) and Predose Concentration (Cmin)

    Time frame: Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose

  2. Sulfasalazine Time for Cmax (Tmax) at Steady State

    Time frame: Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose

  3. Sulfasalazine Area Under the Concentration-time Profile From Time 0 to Time Tau, the Dosing Interval (AUCtau) at Steady State

    Time frame: Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose

  4. Sulfapyridine Steady State Cmax and Cmin

    Sulfapyridine and 5-aminosalicylic acid (5-ASA) are primary metabolites of sulfasalazine, the study drug.

    Time frame: Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose

  5. Sulfapyridine Tmax at Steady State

    Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.

    Time frame: Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose

  6. Sulfapyridine AUCtau at Steady State

    Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.

    Time frame: Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose

  7. 5-aminosalicylic Acid (5-ASA) Steady State Cmax and Cmin

    Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.

    Time frame: Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose

  8. 5-aminosalicylic Acid (5-ASA) Tmax at Steady State

    Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.

    Time frame: Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose

  9. 5-aminosalicylic Acid (5-ASA) AUCtau at Steady State

    Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.

    Time frame: Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose

Secondary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs

    An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. TEAEs are defined as newly occurring AEs or those worsening after first dose. AEs comprised both SAEs and non-SAEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Screening through to and including 28 calendar days after the last administration of the investigational product

  2. Number of Participants With Laboratory Test Abnormalities

    Number of participants with laboratory test abnormalities without regard to baseline abnormality. Laboratory test parameters included hematology, coagulation, liver function, renal function, electrolytes,clinical chemistry, and urinalysis (dipstick and microscopy).

    Time frame: Screening, Day 0, and Day 7

  3. Number of Participants With Vital Signs Values Meeting Categorical Summarization Criteria

    Vital sign values which met categorical summarization criteria included: supine/sitting pulse rate less than (\<) 40 or more than (\>) 120 beats per minute (bpm); erect pulse rate \<40 or \>140 bpm; changes from baseline in same posture of systolic blood pressure (SBP) more than or equal to (\>=) 30 millimeters of mercury (mm Hg) or diastolic blood pressure (DBP) \>=20 mm Hg; SBP \<90 mm Hg; and DBP \<50 mm Hg.

    Time frame: Screening, Day 0, and Day 7

07

Results

Posted Feb 23, 2017
Limitations and caveats
The study was terminated prematurely and only 2 participants were enrolled and completed the study.

Participant flow

The last participant enrolled in 2014 but the study was kept open for another 2 years and enrollment was not stopped. However, by 2016, no additional participants were enrolled and thus the study was closed. As such, the basic results for this study are only prepared in 2016 though last participant's last visit was in 2014.

Participant flow — Overall Study
MilestoneSulfasalazine in Juvenile Idiopathic Arthritis
Started2
Completed2
Not completed0

Outcome measures

PrimarySulfasalazine Steady State Maximum Plasma Concentration (Cmax) and Predose Concentration (Cmin)
Time frame:
Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose
Reported as:
Number · micrograms (mcg)/milliliter (mL)
Sulfasalazine Steady State Maximum Plasma Concentration (Cmax) and Predose Concentration (Cmin)
micrograms (mcg)/milliliter (mL)Sulfasalazine in Juvenile Idiopathic Arthritis
Cmax - Value 117.6 (4.51 to 17.6)
Cmax - Value 24.51 (0.988 to 4.28)
Cmin - Value 14.28
Cmin - Value 20.988
PrimarySulfasalazine Time for Cmax (Tmax) at Steady State
Time frame:
Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose
Reported as:
Number · hours (hr)
Sulfasalazine Time for Cmax (Tmax) at Steady State
hours (hr)Sulfasalazine in Juvenile Idiopathic Arthritis
Value 12.02
Value 25.92
PrimarySulfasalazine Area Under the Concentration-time Profile From Time 0 to Time Tau, the Dosing Interval (AUCtau) at Steady State
Time frame:
Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose
Reported as:
Number · mcg*hr/mL
Sulfasalazine Area Under the Concentration-time Profile From Time 0 to Time Tau, the Dosing Interval (AUCtau) at Steady State
mcg*hr/mLSulfasalazine in Juvenile Idiopathic Arthritis
Value 1110
Value 234.7
PrimarySulfapyridine Steady State Cmax and Cmin

Sulfapyridine and 5-aminosalicylic acid (5-ASA) are primary metabolites of sulfasalazine, the study drug.

Time frame:
Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose
Reported as:
Number · mcg/mL
Sulfapyridine Steady State Cmax and Cmin
mcg/mLSulfasalazine in Juvenile Idiopathic Arthritis
Cmax - Value 121.7
Cmax - Value 27.68
Cmin - Value 114.7
Cmin - Value 24.79
PrimarySulfapyridine Tmax at Steady State

Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.

Time frame:
Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose
Reported as:
Number · hr
Sulfapyridine Tmax at Steady State
hrSulfasalazine in Juvenile Idiopathic Arthritis
Value 14.00
Value 211.9
PrimarySulfapyridine AUCtau at Steady State

Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.

Time frame:
Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose
Reported as:
Number · mcg*hr/mL
Sulfapyridine AUCtau at Steady State
mcg*hr/mLSulfasalazine in Juvenile Idiopathic Arthritis
Value 1232
Value 267.3
Primary5-aminosalicylic Acid (5-ASA) Steady State Cmax and Cmin

Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.

Time frame:
Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose
Reported as:
Number · mcg/mL
5-aminosalicylic Acid (5-ASA) Steady State Cmax and Cmin
mcg/mLSulfasalazine in Juvenile Idiopathic Arthritis
Cmax - Value 10.208
Cmax - Value 20.0982
Cmin - Value 10.0439
Cmin - Value 20.0816
Primary5-aminosalicylic Acid (5-ASA) Tmax at Steady State

Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.

Time frame:
Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose
Reported as:
Number · hr
5-aminosalicylic Acid (5-ASA) Tmax at Steady State
hrSulfasalazine in Juvenile Idiopathic Arthritis
Value 10.000
Value 211.9
Primary5-aminosalicylic Acid (5-ASA) AUCtau at Steady State

Sulfapyridine and 5-ASA are primary metabolites of sulfasalazine, the study drug.

Time frame:
Day 7 predose, and 2, 4, 6, 10, and 12 hours postdose
Reported as:
Number · mcg*hr/mL
5-aminosalicylic Acid (5-ASA) AUCtau at Steady State
mcg*hr/mLSulfasalazine in Juvenile Idiopathic Arthritis
Value 11.63
Value 21.04
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs

An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. TEAEs are defined as newly occurring AEs or those worsening after first dose. AEs comprised both SAEs and non-SAEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Screening through to and including 28 calendar days after the last administration of the investigational product
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs
participantsSulfasalazine in Juvenile Idiopathic Arthritis
TEAEs0
SAEs0
Withdrawals due to TEAEs0
SecondaryNumber of Participants With Laboratory Test Abnormalities

Number of participants with laboratory test abnormalities without regard to baseline abnormality. Laboratory test parameters included hematology, coagulation, liver function, renal function, electrolytes,clinical chemistry, and urinalysis (dipstick and microscopy).

Time frame:
Screening, Day 0, and Day 7
Reported as:
Number · participants
Number of Participants With Laboratory Test Abnormalities
participantsSulfasalazine in Juvenile Idiopathic Arthritis
Number of Participants With Laboratory Test Abnormalities1
SecondaryNumber of Participants With Vital Signs Values Meeting Categorical Summarization Criteria

Vital sign values which met categorical summarization criteria included: supine/sitting pulse rate less than (\<) 40 or more than (\>) 120 beats per minute (bpm); erect pulse rate \<40 or \>140 bpm; changes from baseline in same posture of systolic blood pressure (SBP) more than or equal to (\>=) 30 millimeters of mercury (mm Hg) or diastolic blood pressure (DBP) \>=20 mm Hg; SBP \<90 mm Hg; and DBP \<50 mm Hg.

Time frame:
Screening, Day 0, and Day 7
Reported as:
Number · participants
Number of Participants With Vital Signs Values Meeting Categorical Summarization Criteria
participantsSulfasalazine in Juvenile Idiopathic Arthritis
Number of Participants With Vital Signs Values Meeting Categorical Summarization Criteria0

Adverse events

Collected over Screening through to and including 28 calendar days after the last administration of the investigational product.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sulfasalazine in Juvenile Idiopathic Arthritis—0/2 (0%)0/2 (0%)

Baseline characteristics

The only 2 participants who were enrolled and completed the study at study termination were included in all analyses.

Age, Continuous
Age, Continuous(years)Sulfasalazine in Juvenile Idiopathic Arthritis
Mean15.0 ± 1.4
Gender
Gender(Participants)Sulfasalazine in Juvenile Idiopathic Arthritis
Female1
Male1
08

Study locations

2 sites
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Private Office
    Guadalajara, Jalisco 44650, Mexico
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2008
First posted
Mar 18, 2008
Start
Jun 2010
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results first posted
Feb 23, 2017
Last update
Feb 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00637780
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 18, 2008
Start date
Jun 2010
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Feb 23, 2017
Last update
Feb 23, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sulfasalazine

Start the discussion